In recent years, immunotherapy represented by anti-PD-1 therapy has shown promising therapeutic potential in partial preclinical research of glioma (39, 40), but most immunotherapy clinical trials have failed to achieve the expected treatment efficacy (41). This evidence concerns the gene PDCD1 and central nervous system cancer.